To Assess the Efficacy and Safety of the Cardio Formulation in Reducing Oxidized LDL
NCT ID: NCT04317287
Last Updated: 2023-01-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
NA
Total Enrollment
9 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-12-10
Study Completion Date
2021-11-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to assess the efficacy and safety of the Cardio formulation in reducing oxidized LDL \[(Ox LDL (low density lipoprotein)\] in overweight to mildly obese generally healthy adults.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation
NCT04269876
Inflammation
Inflammatory Response
TERMINATED
NA
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
NCT03372733
Cardiovascular Disease
RECRUITING
PHASE2
The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes
NCT00360217
Hypertriglyceridemia (TG>200<500)
Hyperlipidemia
Coronary Artery Disease
+2 more
COMPLETED
NA
Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease
NCT04088240
Elevated Triglycerides
Cardiovascular Risk Factor
TERMINATED
NA
Efficacy Study on the Lipid-lowering Effect of Plant Sterols and Fish Oil
NCT01313988
Healthy
Mildly Elevated Cholesterol Levels
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a double-blind, randomized, placebo-controlled, parallel design study to evaluate the effectiveness of the Cardio formulation in reducing oxidized LDL. Each subject will receive a specific dose of the study product to be taken with a meal daily preferably at the same time each day with water.
Participants will receive questionnaires, assessments, blood tests, vital signs and body composition analysis.
The primary objective is the evaluation of the change in Ox LDL in response to the Cardio formulation at Days 30 and 60 relative to baseline compared with placebo.
The secondary objective is the evaluation of the change in anthropometric measurements, clinical laboratory evaluations, and health survey scores in response to the Cardio formulation at Days 30 and Day 60 relative to baseline compared with placebo.
Participants will receive questionnaires, assessments, blood tests, vital signs and body composition analysis.
The primary objective is the evaluation of the change in Ox LDL in response to the Cardio formulation at Days 30 and 60 relative to baseline compared with placebo.
The secondary objective is the evaluation of the change in anthropometric measurements, clinical laboratory evaluations, and health survey scores in response to the Cardio formulation at Days 30 and Day 60 relative to baseline compared with placebo.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Oxidized Low Density Lipoprotein
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
HEALTH_SERVICES_RESEARCH
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardio formulation
Tomato-based formulation with dietary supplement
Group Type
EXPERIMENTAL
Cardio formulation
Intervention Type
DIETARY_SUPPLEMENT
Tomato-based formulation with dietary supplement softgels
Placebo
Placebo softgels
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DIETARY_SUPPLEMENT
Placebo softgels
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardio formulation
Tomato-based formulation with dietary supplement softgels
Intervention Type
DIETARY_SUPPLEMENT
Placebo
Placebo softgels
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Ambulatory, male or female, 40-75 years of age
2. A BMI of 25-34.9 and/or waist circumference \> 40.0 inches in males and \> 35.0 inches in females
3. Having a fasting LDL cholesterol level of \>100- \<189 mg/dL OR, total cholesterol level of \> 200-\< 239 mg/dL OR triglycerides level of \> 150 mg/dl - \< 199 mg/dl OR blood sugar level \> 100 mg/dl - \< 126 mg/dl based upon the screening laboratory results from the Complete Blood Count (CBC)/Chemistry profile
4. Generally healthy and having no significant difficulty with digestion or absorption of food
5. Has been generally weight stable for the past six months (+ 6 lbs.)
6. Willing and able to give written informed consent
7. Clearly understands the procedures and study requirements
8. Willing and able to comply with all study procedures, including following the recommendations to maintain their usual diet and regular activity, as per protocol
9. Able to communicate, including reading, in English
10. Have not taken any nutritional supplements that may contain any of the components of the study product for a minimum of 14 days before Screening/baseline
2. A BMI of 25-34.9 and/or waist circumference \> 40.0 inches in males and \> 35.0 inches in females
3. Having a fasting LDL cholesterol level of \>100- \<189 mg/dL OR, total cholesterol level of \> 200-\< 239 mg/dL OR triglycerides level of \> 150 mg/dl - \< 199 mg/dl OR blood sugar level \> 100 mg/dl - \< 126 mg/dl based upon the screening laboratory results from the Complete Blood Count (CBC)/Chemistry profile
4. Generally healthy and having no significant difficulty with digestion or absorption of food
5. Has been generally weight stable for the past six months (+ 6 lbs.)
6. Willing and able to give written informed consent
7. Clearly understands the procedures and study requirements
8. Willing and able to comply with all study procedures, including following the recommendations to maintain their usual diet and regular activity, as per protocol
9. Able to communicate, including reading, in English
10. Have not taken any nutritional supplements that may contain any of the components of the study product for a minimum of 14 days before Screening/baseline
Exclusion Criteria
1. Having smoked any cigarette, electronic cigarette, cigar, pipe, or used a recreational drug or any product containing cannabidiol (CBD) or tetrahydrocannabinol (THC) in the past 30 days
2. Donated blood within 30 days before Screening/baseline
3. Inability to provide a venous blood sample
4. Participation in another study within 30 days prior to Screening/baseline
5. Being pregnant or planning on becoming pregnant during study participation; or breast feeding
6. History of allergy or sensitivity to any component of the study products including tomatoes, lycopene, Japanese knotweed (Reynoutria japonica, Fallopia japonica, Polygonum cuspidatum) phytosterols, mixed tocopherols, phytoene and phytofluene and beta carotene, polydatin, resveratrol, gelatin, glycerin, or coconut oil
7. Currently taking or having taken within 30 days before Screening/baseline a cholesterol-lowering medication(s) including 3-hydroxy-3-methylglutaric acid-CoA (HMG-CoA) reductase inhibitors, cholesterol binding resins, niacin \> 500 mg/day, or fibrates
8. Currently taking or having taken within 30 days before Screening/baseline a dietary supplement/food that may affect cholesterol levels including niacin \> 500 mg/day, red yeast rice, red mold dioscorea, guggulipid, policosanol, pantethine \> 300 mg/day, beta-sitosterol, artichoke leaf, L-carnitine, and nuts (including almonds, walnuts, hazelnuts, pecans and pistachios \> 1oz. per day)
9. Currently taking or having taken within 30 days before Screening/baseline a multivitamin/mineral product (unless on a consistent daily intake and unlikely to change during the study period)
10. Currently taking or having taken within 30 days before Screening/baseline a supplemental fiber product (unless on a consistent daily intake and unlikely to change during the study period)
11. Presence of active or recurring clinically significant conditions as follows:
* Diabetes mellitus or other endocrine disease
* Eating disorder
* Acute or chronic inflammatory disease or autoimmune disease
* Cardiovascular disease including heart and blood vessel disease, arrhythmia, heart attack, stroke or heart valve problem
* Gastrointestinal disease including gallbladder problems, gallstones or biliary tract obstruction
* Thyroid disease (unless on a stable dose of medication for 3 months before Screening/baseline and unlikely to change medication or dose during the study period)
* Hypertension (unless on a stable dose of medication for 3 months before Screening/baseline and unlikely to change medication or dose during the study period)
* Neurologic condition/disease
* Cancer (unless skin cancer other than melanoma which has been treated \> 3 years before Screening/baseline)
* Liver, pancreatic, and kidney disease
* Pulmonary disease
* Blood coagulation disorder or other hematologic disease
* Other condition or medication use that would preclude participation in the study in the judgment of the Study Investigator/sub-investigator (Sub-I)
12. Currently taking any medication(s) or treatment for a psychiatric disorder (bipolar disorder, manic disorder, schizophrenia, apathetic \[inherited\] disorder) that include antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), tricyclic and atypical antidepressants; benzodiazepines; CNS depressants dextromethorphan, meperidine, monoamine oxidase inhibitors (MAOIs); pentazocine, phenothiazines and tramadol. These may preclude participation in the study dependent on the judgment of the investigator/sub-investigator.
13. Currently taking or having taken within the 30 days before Screening/baseline any hormone replacement therapy (including dehydroepiandrosterone (DHEA), estrogen, progesterone, or testosterone; except those utilized as a method of birth control and which have been taken for \> 3 months, with no anticipated change for the duration of the study period)
14. Having had a surgical procedure or having an internal medical device which, in the judgment of the Study Investigator/Sub-I, would preclude participation in the study
15. Having abnormal screening laboratory test values including bilirubin \> 2.5 x upper limit of normal (ULN), aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) /serum glutaminic- pyruvic transaminase (SGPT) \> 2.5 x ULN, serum creatinine \> 1.5 mg/dL based upon the screening laboratory results or other lab test result(s) that would preclude study participation in the judgement of the Study Investigator/Sub-I
16. Having blood pressure readings at Screening/baseline \> 140 systolic or \> 90 diastolic on two consecutive readings unless permitted to proceed to the next visit in the judgment of the Study Investigator/Sub-I
17. Currently consumes more than 7 standard alcoholic drinks per week for women and 14 drinks per week for men (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)
18. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges and tangelos
19. History of known or suspected substance abuse (e.g., alcohol, opiates, benzodiazepines or amphetamines).
20. Having any other circumstance that precludes study participation in the judgment of the Study Investigator/Sub-I, including use of other nutritional supplements, which will be evaluated on a case-by-case basis.
2. Donated blood within 30 days before Screening/baseline
3. Inability to provide a venous blood sample
4. Participation in another study within 30 days prior to Screening/baseline
5. Being pregnant or planning on becoming pregnant during study participation; or breast feeding
6. History of allergy or sensitivity to any component of the study products including tomatoes, lycopene, Japanese knotweed (Reynoutria japonica, Fallopia japonica, Polygonum cuspidatum) phytosterols, mixed tocopherols, phytoene and phytofluene and beta carotene, polydatin, resveratrol, gelatin, glycerin, or coconut oil
7. Currently taking or having taken within 30 days before Screening/baseline a cholesterol-lowering medication(s) including 3-hydroxy-3-methylglutaric acid-CoA (HMG-CoA) reductase inhibitors, cholesterol binding resins, niacin \> 500 mg/day, or fibrates
8. Currently taking or having taken within 30 days before Screening/baseline a dietary supplement/food that may affect cholesterol levels including niacin \> 500 mg/day, red yeast rice, red mold dioscorea, guggulipid, policosanol, pantethine \> 300 mg/day, beta-sitosterol, artichoke leaf, L-carnitine, and nuts (including almonds, walnuts, hazelnuts, pecans and pistachios \> 1oz. per day)
9. Currently taking or having taken within 30 days before Screening/baseline a multivitamin/mineral product (unless on a consistent daily intake and unlikely to change during the study period)
10. Currently taking or having taken within 30 days before Screening/baseline a supplemental fiber product (unless on a consistent daily intake and unlikely to change during the study period)
11. Presence of active or recurring clinically significant conditions as follows:
* Diabetes mellitus or other endocrine disease
* Eating disorder
* Acute or chronic inflammatory disease or autoimmune disease
* Cardiovascular disease including heart and blood vessel disease, arrhythmia, heart attack, stroke or heart valve problem
* Gastrointestinal disease including gallbladder problems, gallstones or biliary tract obstruction
* Thyroid disease (unless on a stable dose of medication for 3 months before Screening/baseline and unlikely to change medication or dose during the study period)
* Hypertension (unless on a stable dose of medication for 3 months before Screening/baseline and unlikely to change medication or dose during the study period)
* Neurologic condition/disease
* Cancer (unless skin cancer other than melanoma which has been treated \> 3 years before Screening/baseline)
* Liver, pancreatic, and kidney disease
* Pulmonary disease
* Blood coagulation disorder or other hematologic disease
* Other condition or medication use that would preclude participation in the study in the judgment of the Study Investigator/sub-investigator (Sub-I)
12. Currently taking any medication(s) or treatment for a psychiatric disorder (bipolar disorder, manic disorder, schizophrenia, apathetic \[inherited\] disorder) that include antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), tricyclic and atypical antidepressants; benzodiazepines; CNS depressants dextromethorphan, meperidine, monoamine oxidase inhibitors (MAOIs); pentazocine, phenothiazines and tramadol. These may preclude participation in the study dependent on the judgment of the investigator/sub-investigator.
13. Currently taking or having taken within the 30 days before Screening/baseline any hormone replacement therapy (including dehydroepiandrosterone (DHEA), estrogen, progesterone, or testosterone; except those utilized as a method of birth control and which have been taken for \> 3 months, with no anticipated change for the duration of the study period)
14. Having had a surgical procedure or having an internal medical device which, in the judgment of the Study Investigator/Sub-I, would preclude participation in the study
15. Having abnormal screening laboratory test values including bilirubin \> 2.5 x upper limit of normal (ULN), aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) /serum glutaminic- pyruvic transaminase (SGPT) \> 2.5 x ULN, serum creatinine \> 1.5 mg/dL based upon the screening laboratory results or other lab test result(s) that would preclude study participation in the judgement of the Study Investigator/Sub-I
16. Having blood pressure readings at Screening/baseline \> 140 systolic or \> 90 diastolic on two consecutive readings unless permitted to proceed to the next visit in the judgment of the Study Investigator/Sub-I
17. Currently consumes more than 7 standard alcoholic drinks per week for women and 14 drinks per week for men (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)
18. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges and tangelos
19. History of known or suspected substance abuse (e.g., alcohol, opiates, benzodiazepines or amphetamines).
20. Having any other circumstance that precludes study participation in the judgment of the Study Investigator/Sub-I, including use of other nutritional supplements, which will be evaluated on a case-by-case basis.
Minimum Eligible Age
40 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Supplement Formulators, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Swick, Ph.D
Role: PRINCIPAL_INVESTIGATOR
LIfe Extension
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lfie Extension Clinical Reseach, Inc.
Fort Lauderdale, Florida, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Agarwal S, Rao AV. Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. Lipids. 1998 Oct;33(10):981-4. doi: 10.1007/s11745-998-0295-6.
Reference Type
BACKGROUND
Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62. doi: 10.1016/S0140-6736(05)67402-8. No abstract available.
Reference Type
BACKGROUND
Ali, W., Kushwaha, U., Wamique, M., & et al. (2017). Oxidized LDL as a Biomarker in Metabolic Syndrome. J Diabetes Metab, 8(9), 1-5.
Reference Type
BACKGROUND
Ansari MS, Gupta NP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol. 2004 Sep-Oct;22(5):415-20. doi: 10.1016/j.urolonc.2004.05.009.
Reference Type
BACKGROUND
Anton SD, Embry C, Marsiske M, Lu X, Doss H, Leeuwenburgh C, Manini TM. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol. 2014 Sep;57:181-7. doi: 10.1016/j.exger.2014.05.015. Epub 2014 May 24.
Reference Type
BACKGROUND
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019 Mar 5;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659. No abstract available.
Reference Type
BACKGROUND
Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017;1:35. doi: 10.1038/s41698-017-0038-6. Epub 2017 Sep 25.
Reference Type
BACKGROUND
Bunker CH, McDonald AC, Evans RW, de la Rosa N, Boumosleh JM, Patrick AL. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutr Cancer. 2007;57(2):130-7. doi: 10.1080/01635580701274046.
Reference Type
BACKGROUND
Burton-Freeman B, Talbot J, Park E, Krishnankutty S, Edirisinghe I. Protective activity of processed tomato products on postprandial oxidation and inflammation: a clinical trial in healthy weight men and women. Mol Nutr Food Res. 2012 Apr;56(4):622-31. doi: 10.1002/mnfr.201100649. Epub 2012 Feb 14.
Reference Type
BACKGROUND
Csige I, Ujvarosy D, Szabo Z, Lorincz I, Paragh G, Harangi M, Somodi S. The Impact of Obesity on the Cardiovascular System. J Diabetes Res. 2018 Nov 4;2018:3407306. doi: 10.1155/2018/3407306. eCollection 2018.
Reference Type
BACKGROUND
Carrier A. Metabolic Syndrome and Oxidative Stress: A Complex Relationship. Antioxid Redox Signal. 2017 Mar 20;26(9):429-431. doi: 10.1089/ars.2016.6929. Epub 2016 Dec 19.
Reference Type
BACKGROUND
Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004 Aug;53(8):2087-94. doi: 10.2337/diabetes.53.8.2087.
Reference Type
BACKGROUND
Chen J, Song Y, Zhang L. Effect of lycopene supplementation on oxidative stress: an exploratory systematic review and meta-analysis of randomized controlled trials. J Med Food. 2013 May;16(5):361-74. doi: 10.1089/jmf.2012.2682. Epub 2013 Apr 30.
Reference Type
BACKGROUND
Cheng AS, Cheng YH, Chiou CH, Chang TL. Resveratrol upregulates Nrf2 expression to attenuate methylglyoxal-induced insulin resistance in Hep G2 cells. J Agric Food Chem. 2012 Sep 12;60(36):9180-7. doi: 10.1021/jf302831d. Epub 2012 Aug 29.
Reference Type
BACKGROUND
Clark PE, Hall MC, Borden LS Jr, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R Jr, Lovato J, Harmon M, Torti FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology. 2006 Jun;67(6):1257-61. doi: 10.1016/j.urology.2005.12.035.
Reference Type
BACKGROUND
Clinic, M. (n.d.). PCSK9 inhibtion: A game changer in cholesterol management. Retrieved from Cardiovascular Diseases: 1 https://www.mayoclinic.org/medical-professionals/cardiovascular-diseases/news/pcsk9-inhibition-a-game-changer-in-cholesterol-management/mac-20430713
Reference Type
BACKGROUND
Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res. 2010 Jan;54(1):7-16. doi: 10.1002/mnfr.200900437.
Reference Type
BACKGROUND
Dallal, G. (2017, July 10). www.Randomization.com. Retrieved from Randomization.com: http://www.randomization.com
Reference Type
BACKGROUND
Deplanque X, Muscente-Paque D, Chappuis E. Proprietary tomato extract improves metabolic response to high-fat meal in healthy normal weight subjects. Food Nutr Res. 2016 Oct 4;60:32537. doi: 10.3402/fnr.v60.32537. eCollection 2016.
Reference Type
BACKGROUND
Institute of Medicine (US) Committee on a National Surveillance System for Cardiovascular and Select Chronic Diseases. A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases. Washington (DC): National Academies Press (US); 2011. Available from http://www.ncbi.nlm.nih.gov/books/NBK83166/
Reference Type
BACKGROUND
Drugs.com. (n.d.). Retrieved 2019, from Resveratrol: https://www.drugs.com/resveratrol.html
Reference Type
BACKGROUND
Du J, Sun LN, Xing WW, Huang BK, Jia M, Wu JZ, Zhang H, Qin LP. Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters. Phytomedicine. 2009 Jun;16(6-7):652-8. doi: 10.1016/j.phymed.2008.10.001. Epub 2008 Dec 21.
Reference Type
BACKGROUND
Du QH, Peng C, Zhang H. Polydatin: a review of pharmacology and pharmacokinetics. Pharm Biol. 2013 Nov;51(11):1347-54. doi: 10.3109/13880209.2013.792849. Epub 2013 Jul 18.
Reference Type
BACKGROUND
Gajendragadkar PR, Hubsch A, Maki-Petaja KM, Serg M, Wilkinson IB, Cheriyan J. Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. PLoS One. 2014 Jun 9;9(6):e99070. doi: 10.1371/journal.pone.0099070. eCollection 2014.
Reference Type
BACKGROUND
Gonzalez O, Tobia C, Ebersole J, Novak MJ. Caloric restriction and chronic inflammatory diseases. Oral Dis. 2012 Jan;18(1):16-31. doi: 10.1111/j.1601-0825.2011.01830.x. Epub 2011 Jul 13.
Reference Type
BACKGROUND
Cervantes Gracia K, Llanas-Cornejo D, Husi H. CVD and Oxidative Stress. J Clin Med. 2017 Feb 20;6(2):22. doi: 10.3390/jcm6020022.
Reference Type
BACKGROUND
Grether-Beck S, Marini A, Jaenicke T, Stahl W, Krutmann J. Molecular evidence that oral supplementation with lycopene or lutein protects human skin against ultraviolet radiation: results from a double-blinded, placebo-controlled, crossover study. Br J Dermatol. 2017 May;176(5):1231-1240. doi: 10.1111/bjd.15080. Epub 2017 Mar 15.
Reference Type
BACKGROUND
Gustin DM, Rodvold KA, Sosman JA, Diwadkar-Navsariwala V, Stacewicz-Sapuntzakis M, Viana M, Crowell JA, Murray J, Tiller P, Bowen PE. Single-dose pharmacokinetic study of lycopene delivered in a well-defined food-based lycopene delivery system (tomato paste-oil mixture) in healthy adult male subjects. Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):850-60.
Reference Type
BACKGROUND
Hadad N, Levy R. The synergistic anti-inflammatory effects of lycopene, lutein, beta-carotene, and carnosic acid combinations via redox-based inhibition of NF-kappaB signaling. Free Radic Biol Med. 2012 Oct 1;53(7):1381-91. doi: 10.1016/j.freeradbiomed.2012.07.078. Epub 2012 Aug 2.
Reference Type
BACKGROUND
Haseen F, Cantwell MM, O'Sullivan JM, Murray LJ. Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. Prostate Cancer Prostatic Dis. 2009;12(4):325-32. doi: 10.1038/pcan.2009.38. Epub 2009 Sep 1.
Reference Type
BACKGROUND
Heinecke JW. Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander? J Exp Med. 2006 Apr 17;203(4):813-6. doi: 10.1084/jem.20060218. Epub 2006 Apr 10.
Reference Type
BACKGROUND
Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ Res. 2016 Feb 19;118(4):535-46. doi: 10.1161/CIRCRESAHA.115.307611.
Reference Type
BACKGROUND
Holvoet P, De Keyzer D, Jacobs DR Jr. Oxidized LDL and the metabolic syndrome. Future Lipidol. 2008 Dec;3(6):637-649. doi: 10.2217/17460875.3.6.637.
Reference Type
BACKGROUND
Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004 May 24;164(10):1066-76. doi: 10.1001/archinte.164.10.1066.
Reference Type
BACKGROUND
Hurtado-Roca Y, Bueno H, Fernandez-Ortiz A, Ordovas JM, Ibanez B, Fuster V, Rodriguez-Artalejo F, Laclaustra M. Oxidized LDL Is Associated With Metabolic Syndrome Traits Independently of Central Obesity and Insulin Resistance. Diabetes. 2017 Feb;66(2):474-482. doi: 10.2337/db16-0933. Epub 2016 Dec 19.
Reference Type
BACKGROUND
Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W; North Central Cancer Treatment Group. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology. 2007 Feb;69(2):289-94. doi: 10.1016/j.urology.2006.10.019.
Reference Type
BACKGROUND
Jonker D, Kuper CF, Fraile N, Estrella A, Rodriguez Otero C. Ninety-day oral toxicity study of lycopene from Blakeslea trispora in rats. Regul Toxicol Pharmacol. 2003 Jun;37(3):396-406. doi: 10.1016/s0273-2300(03)00013-8.
Reference Type
BACKGROUND
Kim JY, Paik JK, Kim OY, Park HW, Lee JH, Jang Y, Lee JH. Effects of lycopene supplementation on oxidative stress and markers of endothelial function in healthy men. Atherosclerosis. 2011 Mar;215(1):189-95. doi: 10.1016/j.atherosclerosis.2010.11.036. Epub 2010 Dec 9.
Reference Type
BACKGROUND
Li L, Shen C, Huang YX, Li YN, Liu XF, Liu XM, Liu JH. A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro. Molecules. 2018 Sep 19;23(9):2397. doi: 10.3390/molecules23092397.
Reference Type
BACKGROUND
Marino G, Pietrocola F, Madeo F, Kroemer G. Caloric restriction mimetics: natural/physiological pharmacological autophagy inducers. Autophagy. 2014;10(11):1879-82. doi: 10.4161/auto.36413.
Reference Type
BACKGROUND
Misra R, Mangi S, Joshi S, Mittal S, Gupta SK, Pandey RM. LycoRed as an alternative to hormone replacement therapy in lowering serum lipids and oxidative stress markers: a randomized controlled clinical trial. J Obstet Gynaecol Res. 2006 Jun;32(3):299-304. doi: 10.1111/j.1447-0756.2006.00410.x.
Reference Type
BACKGROUND
Mozos I, Stoian D, Caraba A, Malainer C, Horbanczuk JO, Atanasov AG. Lycopene and Vascular Health. Front Pharmacol. 2018 May 23;9:521. doi: 10.3389/fphar.2018.00521. eCollection 2018.
Reference Type
BACKGROUND
Office of New Drugs. (2005). Guidance for Industry on esitmating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Federal Register, 70(140), 1-37. Retrieved from https://www.fda.gov/media/72309/download
Reference Type
BACKGROUND
Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipoprotein. Methods Mol Biol. 2010;610:403-17. doi: 10.1007/978-1-60327-029-8_24.
Reference Type
BACKGROUND
Program, I. I. (2012, April 18). Lycopene Handling. Retrieved from United States Department of Agriculture: https://www.ams.usda.gov/sites/default/files/media/Lycopene%20TR.pdf
Reference Type
BACKGROUND
Rosner, B. (n.d.). Hypothesis Testing: Two-Sample Inference- Estimation of Sample Size and Power for Comparing Two Means. In B. Posner, Fundamentals of Biostatistics. Cengage Learning.
Reference Type
BACKGROUND
Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018 Feb 26;20(2):12. doi: 10.1007/s11906-018-0812-z.
Reference Type
BACKGROUND
Schwarz S, Obermuller-Jevic UC, Hellmis E, Koch W, Jacobi G, Biesalski HK. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr. 2008 Jan;138(1):49-53. doi: 10.1093/jn/138.1.49.
Reference Type
BACKGROUND
Srinivasan M, Sudheer AR, Pillai KR, Kumar PR, Sudhakaran PR, Menon VP. Lycopene as a natural protector against gamma-radiation induced DNA damage, lipid peroxidation and antioxidant status in primary culture of isolated rat hepatocytes in vitro. Biochim Biophys Acta. 2007 Apr;1770(4):659-65. doi: 10.1016/j.bbagen.2006.11.008. Epub 2006 Nov 23.
Reference Type
BACKGROUND
Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MKC, Kunz I, Schrauwen-Hinderling VB, Blaak E, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011 Nov 2;14(5):612-22. doi: 10.1016/j.cmet.2011.10.002.
Reference Type
BACKGROUND
Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS; Alzheimer's Disease Cooperative Study. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20;85(16):1383-91. doi: 10.1212/WNL.0000000000002035. Epub 2015 Sep 11.
Reference Type
BACKGROUND
Williams, J., Ensor, M., Smith, R., & et al. (2016). 4-week tosicity and toxicokinetic oral gavage study with polydatin in rats. WebmedCentral TOXICOLOGY, 7(11), 1-19. doi:wmc995231
Reference Type
BACKGROUND
www.Randomization.com. (2017, July 10). Retrieved from Randomization.com: http://www.randomization.com
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL099
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluating the Relationship Between Fatty Acids and Heart Disease
NCT00404872
COMPLETED
Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
NCT00504309
COMPLETED
NA
Investigation Into the Effects of Krill Oil vs. Fish Oil on Markers of Cardiovascular Disease
NCT01705678
COMPLETED
NA
Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation/Discomfort
NCT04819646
COMPLETED
NA
A Human In Vivo Feeding Study Of The Blood Monocyte Response To Dietary Lipid Intake
NCT02101346
TERMINATED
NA
Cod Liver Oil for Covid-19 Prevention Study
NCT04609423
COMPLETED
PHASE4
Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles
NCT03203512
COMPLETED
NA
Fish Oil and Cardiovascular Suboptimal Health
NCT02103517
COMPLETED
PHASE3
SPM Regulation by Fish Oil Supplements in Healthy Volunteers
NCT03347006
COMPLETED
NA
Omega-3 Fatty Acids Supplementation and Atherothrombotic Biomarkers in Type 2 Diabetes and Cardiovascular Disease.
NCT02178501
COMPLETED
NA
Omega 3 Action on Cardiovascular Risk Factors in Patients Treated With Statins
NCT00976872
COMPLETED
NA
Omega 3 Polyunsaturated Fatty Acid Supplements (PUFAs) and Microvolt T Wave Alternans (TWA) in Patients With Ventricular Arrhythmia
NCT00507390
WITHDRAWN
PHASE4
An Evaluation of Omega-3 Fatty Acid
NCT03017651
COMPLETED
PHASE1
Effect of a Mediterranean Diet and Omega-3 Fatty Acids on Oxidative Stress and Endothelial Progenitor Cells (EPC's)
NCT00166088
COMPLETED
PHASE2
Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels in Red Blood Cells and Omega-3 Index
NCT01749202
COMPLETED
NA
Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes
NCT01449773
COMPLETED
NA
Evaluating the Effects of Omega-3 Fatty Acids on Heart Disease and Behavior
NCT00663871
COMPLETED
NA
Impact of Fish Oil Monoglycerides on the Modulation of Mitochondrial Functions and Lactate Threshold
NCT03915535
TERMINATED
PHASE4
Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy
NCT01690312
COMPLETED
NA
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
NCT00935766
TERMINATED
PHASE3
Oxidized Omega-3 Supplements With Different Oxidation
NCT01799720
COMPLETED
NA
Nutrition Intervention to Decrease Symptoms in Patients With Heart Failure
NCT01733017
COMPLETED
PHASE2
Effects of Omega-3 Fatty Acid Supplementation and Physical Training on Metabolic Health
NCT06533891
WITHDRAWN
NA
Krill Oil Study Compared to Fish Oil
NCT01323036
COMPLETED
NA
Change in Omega 3 Index in Healthy Adults With OmeGo or a Standard Omega-3 Oil Supplement
NCT06802068
ACTIVE_NOT_RECRUITING
NA